Yamada Shinya, Yasuhara Atsuhiro, Kawaoka Yoshihiro
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Department of Pathobiological Sciences, School of Veterinary Sciences, Influenza Research Institute, University of Wisconsin-Madison, Madison, WI, United States.
Front Microbiol. 2019 Sep 4;10:2031. doi: 10.3389/fmicb.2019.02031. eCollection 2019.
Currently, influenza vaccines are produced using embryonated chicken eggs. Recently, recombinant influenza vaccines have been developed as a potential alternative to egg-grown vaccines. In this study, we evaluated the efficacy of soluble recombinant hemagglutinin (HA) protein produced in human cell culture (Expi293F cells) as an influenza vaccine against homosubtypic and heterosubtypic influenza virus challenges in mice. Mice were immunized intramuscularly with purified soluble HA protein of H1N1pdm09 virus and then challenged with a lethal dose of H1N1pdm09, seasonal H3N2, or highly pathogenic avian influenza (HPAI) H5N1 virus. Vaccinated mice showed better morbidity than mock-vaccinated mice following H1N1pdm09 challenge. By contrast, all mice died following H3N2 challenge. Interestingly, all vaccinated mice survived challenge with H5N1 virus, whereas all mock-vaccinated mice died. These results suggest that intramuscular immunization with recombinant HA proteins produced in Expi 293F cells could be of value in influenza vaccine strategies.
目前，流感疫苗是通过鸡胚生产的。最近，重组流感疫苗已被开发出来，作为鸡蛋培养疫苗的一种潜在替代品。在本研究中，我们评估了在人细胞培养（Expi293F细胞）中产生的可溶性重组血凝素（HA）蛋白作为流感疫苗，针对小鼠体内同亚型和异亚型流感病毒攻击的效力。用H1N1pdm09病毒的纯化可溶性HA蛋白对小鼠进行肌肉注射免疫，然后用致死剂量的H1N1pdm09、季节性H3N2或高致病性禽流感（HPAI）H5N1病毒进行攻击。在H1N1pdm09攻击后，接种疫苗的小鼠比未接种疫苗的小鼠发病率更低。相比之下，所有小鼠在H3N2攻击后死亡。有趣的是，所有接种疫苗的小鼠在H5N1病毒攻击后存活下来，而所有未接种疫苗的小鼠死亡。这些结果表明，用Expi 293F细胞中产生的重组HA蛋白进行肌肉注射免疫在流感疫苗策略中可能具有价值。
